# Dear Abby: Marijuana Legal but Adolescent Cannabis Binge Use Raises Concerns > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/adolescent-cannabis-binge-use-concerns-legalization/ > **Published:** 2026-04-25T03:12:14-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:58:30-04:00 > **Clinical Summary:** Explore adolescent cannabis binge use risks despite legalization and the importance of screening for cannabis use disorder in youth. --- ✦ New CED Clinical Relevance #5 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. Mental HealthSafetyPolicy Clinical Summary This advice column piece describes a family’s concern about a relative’s problematic [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) despite legalization in their jurisdiction, highlighting the disconnect between legal availability and individual vulnerability to harmful consumption patterns. The article underscores that legal status does not eliminate cannabis-related harms, particularly regarding binge use and potential addiction, which remain clinically relevant issues regardless of regulatory environment. For physicians, this case illustrates the importance of screening all patients for [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) and problematic consumption patterns, as legalization may create a false sense of safety and reduce patient disclosure of concerning use. The piece demonstrates that family members often recognize problematic use before patients themselves do, making collateral history valuable in clinical assessment. Clinicians should counsel patients and families that [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) does not negate the risks of dependence, intoxication-related injuries, or exacerbation of mental health conditions in susceptible individuals. The practical takeaway for clinicians is to maintain vigilant screening for [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) in all patients and educate both patients and families that legal availability does not eliminate the need for cautious, controlled use. Dr. Caplan’s Take “The legality of cannabis in a state doesn’t change my clinical obligation to address problematic use patterns with the same directness I would with alcohol, and in my experience, relatives often see the behavioral signs of [cannabis dependence](https://cedclinic.com/ptsd-cannabis-dependence-veterans-social-support/) before patients themselves do, which makes family input valuable in the clinical conversation.” Clinical Perspective While legalization efforts across states have improved cannabis access and reduced criminal justice burden, clinicians should recognize that legal availability does not eliminate substance use concerns or guarantee safe consumption patterns. The normalization of cannabis in jurisdictions where it is legally available may paradoxically complicate screening conversations, as patients and families may underestimate risks associated with frequent or high-dose use, particularly regarding cognitive effects in younger users and impaired driving. Healthcare providers need to maintain clinical vigilance for problematic use patterns regardless of legal status, understanding that family members—as illustrated in this advice column scenario—often recognize concerning behaviors before patients do. Incorporating non-judgmental substance use screening into routine primary care and mental health visits, alongside education about dose-dependent risks and signs of [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) disorder, remains essential clinical practice even in permissive legal environments. Providers should be prepared to offer evidence-based counseling and referral pathways for patients and concerned family members, recogn 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/mental-health/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Dear%20Abby%3A%20%3Cb%3EMarijuana%3C%2Fb%3E%20may%20be%20legal%20here%2C%20but%20I%20can%E2%80%99t%20ignore%20relatives%E2%80%99%20dangerous%20binge%20%E2%80%93%20syrac...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2Fdear-abby-marijuana-may-be-legal-here-but-i-cant-ignore-relatives-dangerous-binge-syracuse-com%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fdear-abby-marijuana-may-be-legal-here-but-i-cant-ignore-relatives-dangerous-binge-syracuse-com%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Dear%20Abby%3A%20%3Cb%3EMarijuana%3C%2Fb%3E%20may%20be%20legal%20here%2C%20but%20I%20can%E2%80%99t%20ignore%20relatives%E2%80%99%20dangerous%20binge%20%E2%80%93%20syrac...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2Fdear-abby-marijuana-may-be-legal-here-but-i-cant-ignore-relatives-dangerous-binge-syracuse-com%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Everyday Marijuana Mistakes That Could Lead to Criminal Charges – PR Newswire](https://cedclinic.com/legal-risks-cannabis-possession-avoid-criminal-charges/) Learn about common marijuana mistakes that can have legal consequences, highlighting the importance of responsible use. [Read More](https://cedclinic.com/legal-risks-cannabis-possession-avoid-criminal-charges/) [Why the future of marijuana legalization remains hazy despite high public support](https://cedclinic.com/cannabis-legalization-implementation-challenges-patient-access/) Explore the challenges in marijuana legalization and patient access despite widespread public approval. [Explore Insights](https://cedclinic.com/cannabis-legalization-implementation-challenges-patient-access/) Dillon Brooks DUI arrest shifts to marijuana – MSN A case study on marijuana-related DUI arrest emphasizing the risks of cannabis intoxication and legal implications. Learn More ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).